Stock listing
KRX:237690 St Pharm Co., Ltd. (에스티팜) 주가
Follow St Pharm Co., Ltd. into a list and get an email when it puts out news.
Share price · KRX:237690
₩71,600 KRW +1,400 (+2.0%)
Close on Nov 20, 2026
- Day range
- ₩71,300 – ₩75,000 KRWNov 20, 2026
- Volume
- 80,423 sharesNov 20, 2026
- Market cap
- ₩1.34T KRWAt the close on Nov 20, 2026 · price × 18.66M shares outstanding
- 52-week range
- ₩68,900 – ₩172,100 KRWLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- ₩12.61B KRWMedian day 88,020 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · KRX:237690 · KRW, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| ₩71,600 | +1,400 | +2.0% | ₩73,000 | ₩75,000 | ₩71,300 | 80,423 | |
| ₩70,200 | -800 | -1.1% | ₩71,100 | ₩72,000 | ₩69,400 | 50,488 | |
| ₩71,000 | -200 | -0.3% | ₩69,800 | ₩72,400 | ₩69,100 | 53,975 | |
| ₩71,200 | -500 | -0.7% | ₩72,600 | ₩73,400 | ₩70,300 | 57,159 | |
| ₩71,700 | -1,200 | -1.6% | ₩73,600 | ₩75,000 | ₩71,500 | 113,755 | |
| ₩72,900 | -2,100 | -2.8% | ₩74,300 | ₩75,800 | ₩72,000 | 79,923 | |
| ₩75,000 | -500 | -0.7% | ₩74,300 | ₩76,400 | ₩73,800 | 84,759 | |
| ₩75,500 | +4,000 | +5.6% | ₩72,400 | ₩76,500 | ₩72,200 | 115,872 | |
| ₩71,500 | -1,100 | -1.5% | ₩71,400 | ₩73,800 | ₩70,600 | 77,697 | |
| ₩72,600 | -1,800 | -2.4% | ₩69,400 | ₩74,500 | ₩69,100 | 126,478 | |
| ₩74,400 | +1,700 | +2.3% | ₩75,000 | ₩78,000 | ₩74,000 | 156,615 | |
| ₩72,700 | +1,300 | +1.8% | ₩71,400 | ₩72,700 | ₩68,900 | 127,371 | |
| ₩71,400 | -1,100 | -1.5% | ₩71,400 | ₩72,200 | ₩70,600 | 129,680 | |
| ₩72,500 | 0 | 0.0% | ₩71,900 | ₩73,700 | ₩71,200 | 75,970 | |
| ₩72,500 | -1,500 | -2.0% | ₩73,100 | ₩74,700 | ₩71,300 | 113,524 | |
| ₩74,000 | -3,200 | -4.1% | ₩76,200 | ₩77,100 | ₩73,500 | 118,244 | |
| ₩77,200 | -3,200 | -4.0% | ₩80,400 | ₩81,900 | ₩76,200 | 351,538 | |
| ₩80,400 | -8,100 | -9.2% | ₩89,000 | ₩89,900 | ₩76,600 | 255,946 | |
| ₩88,500 | -1,400 | -1.6% | ₩88,400 | ₩91,300 | ₩88,000 | 43,156 | |
| ₩89,900 | +100 | +0.1% | ₩89,500 | ₩91,200 | ₩88,700 | 66,573 | |
| ₩89,800 | -3,000 | -3.2% | ₩92,700 | ₩92,900 | ₩88,700 | 53,888 | |
| ₩92,800 | +600 | +0.7% | ₩93,200 | ₩95,800 | ₩92,000 | 49,045 | |
| ₩92,200 | -2,300 | -2.4% | ₩92,700 | ₩95,300 | ₩91,300 | 56,200 | |
| ₩94,500 | +3,200 | +3.5% | ₩90,600 | ₩94,600 | ₩84,900 | 102,515 | |
| ₩91,300 | +7,500 | +8.9% | ₩83,900 | ₩93,400 | ₩83,900 | 149,079 | |
| ₩83,800 | -2,100 | -2.4% | ₩84,200 | ₩85,200 | ₩82,100 | 94,716 | |
| ₩85,900 | -100 | -0.1% | ₩85,300 | ₩88,700 | ₩84,600 | 79,628 | |
| ₩86,000 | -3,000 | -3.4% | ₩86,400 | ₩87,300 | ₩83,600 | 67,422 | |
| ₩89,000 | -3,900 | -4.2% | ₩94,200 | ₩94,700 | ₩88,300 | 74,967 | |
| ₩92,900 | -3,500 | -3.6% | ₩96,800 | ₩96,900 | ₩91,800 | 101,364 | |
| ₩96,400 | -500 | -0.5% | ₩97,600 | ₩98,900 | ₩95,400 | 90,822 | |
| ₩96,900 | +3,600 | +3.9% | ₩93,600 | ₩99,000 | ₩93,500 | 154,818 | |
| ₩93,300 | -2,300 | -2.4% | ₩95,000 | ₩96,000 | ₩92,400 | 62,574 | |
| ₩95,600 | +3,900 | +4.3% | ₩91,500 | ₩95,800 | ₩91,000 | 124,179 | |
| ₩91,700 | -1,600 | -1.7% | ₩92,900 | ₩93,700 | ₩91,700 | 44,963 | |
| ₩93,300 | +200 | +0.2% | ₩92,400 | ₩93,500 | ₩91,100 | 53,516 | |
| ₩93,100 | +1,800 | +2.0% | ₩92,800 | ₩94,700 | ₩92,100 | 102,158 | |
| ₩91,300 | +700 | +0.8% | ₩91,100 | ₩92,800 | ₩90,200 | 48,558 | |
| ₩90,600 | -400 | -0.4% | ₩92,100 | ₩93,000 | ₩90,500 | 42,996 | |
| ₩91,000 | -1,700 | -1.8% | ₩93,000 | ₩93,300 | ₩90,400 | 60,228 | |
| ₩92,700 | +800 | +0.9% | ₩93,300 | ₩94,000 | ₩90,600 | 142,406 | |
| ₩91,900 | +1,500 | +1.7% | ₩91,300 | ₩92,200 | ₩90,000 | 50,063 | |
| ₩90,400 | +900 | +1.0% | ₩89,000 | ₩90,800 | ₩88,100 | 58,881 | |
| ₩89,500 | +700 | +0.8% | ₩88,000 | ₩91,100 | ₩87,900 | 64,734 | |
| ₩88,800 | -1,200 | -1.3% | ₩88,800 | ₩89,100 | ₩87,400 | 61,223 | |
| ₩90,000 | -1,800 | -2.0% | ₩89,000 | ₩90,400 | ₩88,700 | 83,248 | |
| ₩91,800 | +800 | +0.9% | ₩90,000 | ₩91,800 | ₩87,700 | 145,820 | |
| ₩91,000 | -900 | -1.0% | ₩90,600 | ₩91,500 | ₩89,100 | 146,179 | |
| ₩91,900 | +200 | +0.2% | ₩91,800 | ₩94,000 | ₩91,000 | 107,031 | |
| ₩91,700 | -9,500 | -9.4% | ₩96,200 | ₩96,300 | ₩90,600 | 370,160 | |
| ₩101,200 | +2,200 | +2.2% | ₩99,600 | ₩101,700 | ₩98,800 | 45,260 | |
| ₩99,000 | -2,200 | -2.2% | ₩101,300 | ₩102,300 | ₩98,200 | 63,258 | |
| ₩101,200 | -1,800 | -1.7% | ₩103,000 | ₩105,700 | ₩100,600 | 85,218 | |
| ₩103,000 | -2,200 | -2.1% | ₩103,700 | ₩105,500 | ₩101,800 | 76,369 | |
| ₩105,200 | -5,000 | -4.5% | ₩108,500 | ₩108,500 | ₩102,000 | 118,915 | |
| ₩110,200 | -700 | -0.6% | ₩109,800 | ₩112,800 | ₩108,900 | 166,152 | |
| ₩110,900 | +900 | +0.8% | ₩108,600 | ₩112,200 | ₩108,200 | 151,997 | |
| ₩110,000 | +3,300 | +3.1% | ₩108,800 | ₩112,000 | ₩108,700 | 165,740 | |
| ₩106,700 | -3,500 | -3.2% | ₩106,000 | ₩107,000 | ₩102,500 | 197,455 | |
| ₩110,200 | +10,500 | +10.5% | ₩101,400 | ₩112,000 | ₩101,400 | 335,571 | |
| ₩99,700 | -11,200 | -10.1% | ₩105,500 | ₩107,300 | ₩97,900 | 419,835 | |
| ₩110,900 | +11,600 | +11.7% | ₩121,400 | ₩121,500 | ₩105,000 | 1,411,054 |
- Ticker
- KRX:237690
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- KRX
- Currency
- KRW
What changed lately
Latest news release · Apr 27, 2026
St Pharm Q1 Operating Profit 11.5 Billion Won, Up 1024.6% From Year Earlier
Latest news
St Pharm Q1 Operating Profit 11.5 Billion Won, Up 1024.6% From Year Earlier
Apr 27, 2026
Closed ₩167,500 (+13.2%) on Apr 27, 2026
St Pharm Wins 90 Billion Won Order
Mar 16, 2026
Closed ₩155,100 (-3.5%) on Mar 16, 2026
St Pharm Q4 Operating Profit 26.4 Billion Won, Up 16% From Year Earlier
Feb 8, 2026
Closed ₩154,800 (+5.5%) on Feb 9, 2026
St Pharm Co Ltd - Confirmed Contract Amount 82.5 Billion Won
Jan 22, 2026
Closed ₩139,600 (+16.2%) on Jan 23, 2026
St Pharm Co., Ltd. on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 4 in the last 12 months · 5 in all · newest Apr 27, 2026 · oldest 2025
- Decks
- 2 decks · latest February 2023
Valuation
P/E 17.4× against a median of 28.0×: 2nd lowest of 6 Diagnostics & research services companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- ₩1.17T KRW
- P/E
- 17.4×
- EV/sales
- 3.0×
- EV/EBITDA
- 11.1×
- Price/book
- 2.1×
- Gross margin
- 40.2%
- Operating margin
- 18.3%
- Net margin
- 19.9%
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| St Pharm Co., Ltd. · KRX:237690 | US$992.8M | US$866.1M | 17.4× | 3.0× | 11.1× | 2.1× | 19.9% | 0.0× | n/a |
| Vcanbio Cell & Gene Engineering Corp., Ltd. Class A · SSE:600645 | US$1.06B | US$786.1M | 62.8× | 3.8× | n/a | 1.9× | 8.2% | 0.0× | n/a |
| Beijing Strong Biotechnologies Inc Class A · SZSE:300406 | US$1.05B | US$1.13B | 28.0× | 5.5× | n/a | 1.9× | 18.2% | 0.3× | n/a |
| Freenome, Inc. · NASDAQ:FRNM | US$1.04B | US$863.3M | 9.5× | n/a | n/a | 2.2× | n/a | 0.0× | n/a |
| Maravai LifeSciences Holdings, Inc. · NASDAQ:MRVI | US$1.04B | US$1.11B | n/a | 5.2× | n/a | 5.3× | −30.8% | 0.8× | 1.56 |
| Suzhou Novoprotein Scientific Co., Ltd. Class A · SSE:688137 | US$1.02B | US$909.1M | n/a | 38.0× | n/a | 3.4× | −60.8% | 0.0× | n/a |
| Castle Biosciences, Inc. · NASDAQ:CSTL | US$1.01B | US$745.1M | n/a | 2.0× | n/a | 2.1× | −6.1% | 0.0× | 1.00 |
| Guangzhou Wondfo Biotech Co., Ltd. Class A · SZSE:300482 | US$1.01B | US$785.0M | n/a | 2.7× | n/a | 1.2× | −3.2% | 0.0× | n/a |
| Daan Gene Co., Ltd. Class A · SZSE:002030 | US$990.1M | US$810.9M | n/a | 7.0× | n/a | 0.9× | −95.7% | 0.0× | n/a |
| Amoy Diagnostics Co., Ltd. Class A · SZSE:300685 | US$967.3M | US$801.3M | 18.8× | 4.4× | n/a | 3.3× | 28.5% | 0.1× | n/a |
| Novogene Co., Ltd. Class A · SSE:688315 | US$949.6M | US$685.6M | 43.1× | 2.0× | n/a | 2.3× | 6.4% | 0.0× | n/a |
| Median of the others | US$1.02B | US$806.1M | 28.0× | 4.4× | 2.1× | −3.2% | 0.0× | 1.28 |
Forecasts
Analysts' consensus from EODHD, read Nov 17, 2026. Not 6ix's view and not investment advice.
- Price target
- 143000.00 KRW · Analysts' mean
- EPS, year to Dec 2026
- 2415.00 · 7 analysts
- Revenue, year to Dec 2026
- 413B · 8 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Cheol-Hong Kim | CEO, HAON Accounting Corporation |
| Moo-Je Sung | CEO |
| Mooje Sung | President and CEO |
Board
| Director | Role |
|---|---|
| Cheol-Hong Kim | CEO, HAON Accounting Corporation |
| Dong-Pyo Kim | Professor, Department of chemical Engineering |
| Moo-Je Sung | CEO |
| Seung-Beom Han | Managing Attorney, the Way Law Firm |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q1 2025 | Apr 30, 2025 · After close | −0.1% |
| Q3 2024 | Nov 12, 2024 · After close | −4.6% |
| Q2 2024 | Jul 25, 2024 · After close | +5.5% |
| Q1 2024 | May 2, 2024 · After close | +8.7% |
| Q4 2023 | Mar 25, 2024 · Before open | +2.6% |
| Q3 2023 | Nov 14, 2023 · After close | +1.4% |
| Q2 2023 | Aug 14, 2023 · After close | −2.9% |
| Q1 2023 | Apr 28, 2023 · After close | +13.9% |
| Q4 2022 | Feb 16, 2023 · After close | −2.4% |
| Q3 2022 | Oct 31, 2022 · After close | −8.6% |
All 17 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q2 2022 | Aug 8, 2022 · After close | +4.2% |
| Q1 2022 | May 16, 2022 · After close | +2.0% |
| Q4 2021 | Feb 24, 2022 · After close | +5.0% |
| Q3 2021 | Oct 28, 2021 · Before open | +2.6% |
| Quarter to Jun 30, 2021 | Jul 28, 2021 · After close | +3.0% |
| Quarter to Mar 31, 2021 | Apr 28, 2021 · After close | −9.9% |
| Quarter to Dec 31, 2020 | Jan 25, 2021 · After close | −2.5% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (February 2023) | Investor deck | 24 slides | February 2023 |
| Investor Presentation (January 2023) | Investor deck | 26 slides | January 2023 |
Financials
Annual, in KRW
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 331.7B | 273.8B | 285.0B | 249.3B | 165.6B | 124.1B | 93.3B | 97.7B | 202.8B | 200.4B |
| Cost of revenue | 195.5B | 177.6B | 172.9B | 160.4B | 107.9B | 104.1B | 94.9B | 95.0B | 123.0B | 107.4B |
| Gross profit | 136.2B | 96.2B | 112.1B | 88.9B | 57.7B | 20.0B | -1.63B | 2.78B | 79.8B | 93.0B |
| Research and development | 23.7B | 22.1B | 30.4B | 26.3B | 18.2B | 13.2B | 15.1B | 8.77B | 9.66B | 8.58B |
| Selling, general and administrative | 12.6B | 42.5B | 44.7B | 40.3B | 31.1B | 23.0B | 9.49B | 9.47B | 8.15B | 6.76B |
| Operating income | 54.9B | 27.6B | 33.5B | 17.9B | 5.58B | -18.8B | -26.7B | -15.6B | 61.2B | 77.6B |
| Depreciation and amortization | 29.9B | 24.6B | 23.0B | 17.0B | 14.4B | 14.1B | 11.2B | 9.23B | 11.6B | 10.8B |
| EBITDA | 84.8B | 52.2B | 56.5B | 34.8B | 20.0B | -4.75B | -15.5B | -6.42B | 72.7B | 88.3B |
| Interest expense | 4.04B | 7.74B | 6.11B | 2.87B | 5.16B | 644.6M | 0 | 0 | 0 | 0 |
| Income before tax | 58.7B | 42.7B | 23.4B | 19.2B | 1.26B | -16.8B | -25.0B | -13.4B | 59.2B | 80.5B |
| Income tax | -2.12B | -3.67B | -6.44B | -4.12B | 14.2B | 19.1B | ||||
| Net income | 55.0B | 34.7B | 19.6B | 18.0B | 3.31B | -12.1B | -18.5B | -9.27B | 45.0B | 61.4B |
| Earnings per share, basic | 2,656.95 | 1,722.42 | 1,041.07 | 957.00 | 176.09 | -651.11 | -993.18 | -496.78 | 2,411.93 | 3,323.12 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 30.5B | 63.4B | 50.1B | 50.2B | 27.3B | 8.70B | 74.7M | 47.7B | 72.3B | 55.2B |
| Short-term investments | 60.4B | 57.5B | 40.0B | 10 | 54.0B | 102.0B | 38.2B | 60.0B | 60.0B | 60.0B |
| Receivables | 96.7B | 67.8B | 120.6B | 94.2B | 62.9B | 45.4B | 35.7B | 15.9B | 31.7B | 13.7B |
| Inventory | 169.5B | 127.0B | 120.7B | 107.6B | 80.8B | 45.4B | 40.9B | 40.7B | 58.0B | 91.4B |
| Current assets | 372.7B | 330.1B | 348.4B | 263.2B | 244.1B | 235.6B | 144.2B | 167.3B | 225.2B | 224.9B |
| Property, plant and equipment | 338.7B | 280.1B | 257.9B | 210.2B | 175.6B | 171.0B | 169.1B | 151.6B | 138.4B | |
| Goodwill | 11.8B | 10.6B | 9.95B | 8.95B | 8.46B | 8.04B | 6.69B | |||
| Total assets | 782.6B | 721.9B | 675.4B | 570.7B | 498.6B | 445.6B | 341.1B | 345.5B | 381.5B | 367.8B |
| Accounts payable | 11.8B | 10.6B | 17.7B | 18.1B | 12.9B | 4.69B | 7.16B | 3.09B | 3.11B | 13.7B |
| Current liabilities | 164.8B | 133.3B | 83.7B | 179.2B | 75.4B | 18.6B | 16.2B | 9.95B | 28.6B | 51.5B |
| Long-term debt | 43.3B | 159.7B | 16.7B | 91.5B | 125.6B | 15.1B | 97.5M | 117.0M | 136.5M | |
| Total debt | 126.0B | 15.6B | ||||||||
| Total liabilities | 189.6B | 218.9B | 288.5B | 233.0B | 175.6B | 150.2B | 40.1B | 13.9B | 30.4B | 54.5B |
| Shareholders' equity | 593.4B | 503.1B | 384.6B | 337.6B | 323.0B | 295.3B | 301.0B | 331.6B | 351.1B | 313.2B |
| Shares outstanding | 20.7M | 20.2M | 18.8M | 18.8M | 18.8M | 18.7M | 18.7M | 18.7M | 18.7M | 18.5M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 14.0B | 109.5B | 1.30B | 7.03B | 7.27B | -20.9B | -30.5B | 10.8B | 54.4B | 50.8B |
| Capital spending | -47.3B | -83.2B | -43.4B | -60.7B | -51.8B | -17.0B | -6.22B | -27.2B | -27.7B | -16.0B |
| Free cash flow | -33.3B | 26.2B | -42.1B | -53.6B | -44.6B | -38.4B | -36.7B | -16.4B | 26.7B | 34.7B |
| Cash from investing | -86.5B | -82.4B | -5.72B | -8.03B | -69.1B | -9.77B | -26.8B | -26.3B | -93.2B | |
| Cash from financing | -11.0B | 81.4B | 10.8B | -115.6M | 115.9B | 5.32B | -9.01B | -9.13B | 85.2B | |
| Dividends paid | -10.1B | -9.40B | -9.40B | -9.40B | -9.33B | -9.33B | -9.24B | -2.95B | ||
| Share buybacks | 1.15B | 132.2B | ||||||||
| Change in cash | -32.9B | 13.3B | -103.9M | 11.0B | 578.2M | 25.8B | -34.9B | -24.6B | 17.1B | 43.4B |
Cap table
Built by 6ix from St Pharm Co., Ltd.’s releases
- Common shares
- 18,656,000
- Fully diluted
- 18,656,000
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 18,656,000 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 18,656,000 |
Log in to ask 6ix AI your own questions about St Pharm Co., Ltd.